{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Escherichia coli O157:H7",
      "antimicrobial chemotherapy",
      "hemolytic uremic syndrome",
      "hemorrhagic colitis",
      "shiga toxins"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "23162800",
  "DateCompleted": {
    "Year": "2013",
    "Month": "12",
    "Day": "11"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "10",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2012",
        "Month": "11",
        "Day": "15"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "138",
      "10.3389/fcimb.2012.00138"
    ],
    "Journal": {
      "ISSN": "2235-2988",
      "JournalIssue": {
        "Volume": "2",
        "PubDate": {
          "Year": "2012"
        }
      },
      "Title": "Frontiers in cellular and infection microbiology",
      "ISOAbbreviation": "Front Cell Infect Microbiol"
    },
    "ArticleTitle": "Escherichia coli O157:H7-Clinical aspects and novel treatment approaches.",
    "Pagination": {
      "StartPage": "138",
      "MedlinePgn": "138"
    },
    "Abstract": {
      "AbstractText": [
        "Escherichia coli O157:H7 is a notorious pathogen often contracted by intake of contaminated water or food. Infection with this agent is associated with a broad spectrum of illness ranging from mild diarrhea and hemorrhagic colitis to the potentially fatal hemolytic uremic syndrome (HUS). Treating E. coli O157:H7 infection with antimicrobial agents is associated with an increased risk of severe sequelae such as HUS. The difficulty in treating this bacterium using conventional modalities of antimicrobial agent administration has sparked an interest in investigating new therapeutic approaches to this bacterium. These approaches have included the use of probiotic agents and natural products with variable success rates. In addition, novel modalities and regimen of antimicrobial agent administration have been assessed in an attempt at decreasing their association with aggravating infection outcomes."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Faculty of Medicine, Department of Experimental Pathology, Immunology and Microbiology, American University of Beirut Beirut, Lebanon."
          }
        ],
        "LastName": "Rahal",
        "ForeName": "Elias A",
        "Initials": "EA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kazzi",
        "ForeName": "Natalie",
        "Initials": "N"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Nassar",
        "ForeName": "Farah J",
        "Initials": "FJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Matar",
        "ForeName": "Ghassan M",
        "Initials": "GM"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Front Cell Infect Microbiol",
    "NlmUniqueID": "101585359",
    "ISSNLinking": "2235-2988"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Infective Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Biological Products"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Anti-Infective Agents"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Biological Products"
    },
    {
      "QualifierName": [
        "drug therapy",
        "microbiology",
        "pathology"
      ],
      "DescriptorName": "Diarrhea"
    },
    {
      "QualifierName": [
        "drug therapy",
        "microbiology",
        "pathology"
      ],
      "DescriptorName": "Escherichia coli Infections"
    },
    {
      "QualifierName": [
        "pathogenicity"
      ],
      "DescriptorName": "Escherichia coli O157"
    },
    {
      "QualifierName": [
        "drug therapy",
        "microbiology",
        "pathology"
      ],
      "DescriptorName": "Hemolytic-Uremic Syndrome"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Probiotics"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ]
}